Vivus found ED niche?; Cumberland IPO slammed;

  @FiercePharma: Bayer CEO-in-waiting aims for sales, not margins. Report | Follow @FiercePharma

>  Erectile dysfunction drugs should lose much of their luster in 2012 when generic versions of Pfizer's Viagra hit the market. But drugmaker Vivus seems to think it's found a new, viable niche--helping diabetics resolve ED concerns. Report

> Analysts really know how to hit a drugmaker where it hurts. In a new report, editor Jeff Reeves has slammed Cumberland Pharmaceuticals' IPO as the worst of the last 12 months. Article

> Indian generic drugmaker Orchid Chemicals and Pharmaceuticals has agreed to buy U.S.-based marketing firm Karalex Pharma LLC. The deal should add $20 million to Orchid's revenues this year and allow the Indian firm to directly market products in the U.S. Report

>  Endo Pharmaceuticals and Penwest Pharmaceuticals have settled a suit with Sandoz over rights to sell generic versions of the pain management drug Opana ER. Under the terms of the settlement, Sandoz will get a license to sell a generic version of Opana ER beginning in September 2012. Item

>  Over-the-counter genetic tests seem to be in demand, so much so that major drug chain Walgreens had set plans prepared to distribute them. The problem: the FDA may want to impose tighter regulations than expected on the tests, which could kill this niche. Article

>  Canadian health regulators have decided to make Pfizer include a boxed warning on packaging for smoking cessation drug Champix. The Health Canada agency says it wants to alert users to the drug's possible neuropsychiatric side effects. Item

Biotech News

 @FierceBiotech: Lasers used for painless injections. Report | Follow @FierceBiotech

 @JohnCFierce: For a 2012 insomnia drug, I suspect you'd need more than a placebo comparison to compete in the market. | Follow @JohnCFierce

> Head of Merck's new sleep drug class looks promising in IIb. Story

> Hospira gains EMA OK for Neupogen biosimilar. Report

> Igenica leads a trio of new venture rounds. Story

> Covance plans 300 hires for $15M storage ops. Article

> Icahn makes fresh inroads at Biogen and Genzyme. Item

> HGS files for FDA approval of breakthrough lupus drug. News

Vaccines News

> Vaccine myths fuel some stubborn consumer fears. Piece

> Experimental vax targets a key atherosclerosis trigger. Story

> WHO hits back over H1N1 conflict-of-interest claims. Article

Manufacturing News

> Xcellerex fast-tracks second single-use bioprocessing facility. Report

> Propofol vial reuse linked to hep C outbreak. Report

> Countries report flu vaccine inventory. News

> Nigerian agents detect fake drugs using Raman units. Story

> Lonza starts thinking lean with Raman. Article

And Finally...  Obviously, pharmaceutical companies invest in online marketing. The question is, just how much are they spending?  Item